Clarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9%

MT Newswires Live10:20

Clarity Pharmaceuticals (ASX:CU6) said a participant with metastatic castration-resistant prostate cancer in the phase 2 group expansion phase of the SECuRE trial achieved undetectable disease as assessed by prostate-specific antigen and prostate-specific membrane antigen positron emission tomography, according to a Monday Australian bourse filing.

The trial is evaluating the safety and efficacy of the company's targeted copper therapy-diagnostic product, copper-67-SAR-bisPSMA, for the potential treatment of prostate cancer.

The participant achieved undetectable prostate-specific antigen levels seven weeks after his first cycle of copper-67-SAR-bisPSMA, the filing said. No disease was observed on prostate-specific membrane antigen positron emission tomography after receiving one more cycle of copper-67-SAR-bisPSMA. The participant showed mild related adverse effects, including altered taste, dry eyes, eye pain, fatigue, and salivary gland soreness. No blood-related or renal adverse effects were observed.

This is the fifth patient to achieve undetectable disease by radiographic assessment following copper-67-SAR-bisPSMA treatment, per the filing. The company aims to complete participant recruitment for the group expansion phase this year.

Clarity Pharmaceuticals' shares rose nearly 9% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613084422?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613084422","market":"fut","top_or_hot":-1,"title":"Clarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) said a participant with metastatic castration-resistant prostate cancer in the phase 2 group expansion phase of the SECuRE trial achieved undetectable disease as assessed by prostate-specific antigen and prostate-specific membrane antigen positron emission tomography, according to a Monday Australian bourse filing.</p><p>The trial is evaluating the safety and efficacy of the company's targeted copper therapy-diagnostic product, copper-67-SAR-bisPSMA, for the potential treatment of prostate cancer.</p><p>The participant achieved undetectable prostate-specific antigen levels seven weeks after his first cycle of copper-67-SAR-bisPSMA, the filing said. No disease was observed on prostate-specific membrane antigen positron emission tomography after receiving one more cycle of copper-67-SAR-bisPSMA. The participant showed mild related adverse effects, including altered taste, dry eyes, eye pain, fatigue, and salivary gland soreness. No blood-related or renal adverse effects were observed.</p><p>This is the fifth patient to achieve undetectable disease by radiographic assessment following copper-67-SAR-bisPSMA treatment, per the filing. The company aims to complete participant recruitment for the group expansion phase this year.</p><p>Clarity Pharmaceuticals' shares rose nearly 9% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-23 10:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) said a participant with metastatic castration-resistant prostate cancer in the phase 2 group expansion phase of the SECuRE trial achieved undetectable disease as assessed by prostate-specific antigen and prostate-specific membrane antigen positron emission tomography, according to a Monday Australian bourse filing.</p><p>The trial is evaluating the safety and efficacy of the company's targeted copper therapy-diagnostic product, copper-67-SAR-bisPSMA, for the potential treatment of prostate cancer.</p><p>The participant achieved undetectable prostate-specific antigen levels seven weeks after his first cycle of copper-67-SAR-bisPSMA, the filing said. No disease was observed on prostate-specific membrane antigen positron emission tomography after receiving one more cycle of copper-67-SAR-bisPSMA. The participant showed mild related adverse effects, including altered taste, dry eyes, eye pain, fatigue, and salivary gland soreness. No blood-related or renal adverse effects were observed.</p><p>This is the fifth patient to achieve undetectable disease by radiographic assessment following copper-67-SAR-bisPSMA treatment, per the filing. The company aims to complete participant recruitment for the group expansion phase this year.</p><p>Clarity Pharmaceuticals' shares rose nearly 9% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XME","symbol_name":"金属与采矿指数ETF-SPDR","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2613084422","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613084422","pubTimestamp":1771813245,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clarity Pharmaceuticals  said a participant with metastatic castration-resistant prostate cancer in the phase 2 group expansion phase of the SECuRE trial achieved undetectable disease as assessed by prostate-specific antigen and prostate-specific membrane antigen positron emission tomography, according to a Monday Australian bourse filing.The trial is evaluating the safety and efficacy of the company's targeted copper therapy-diagnostic product, copper-67-SAR-bisPSMA, for the potential treatment of prostate cancer.The participant achieved undetectable prostate-specific antigen levels seven weeks after his first cycle of copper-67-SAR-bisPSMA, the filing said. No disease was observed on prostate-specific membrane antigen positron emission tomography after receiving one more cycle of copper-67-SAR-bisPSMA. The participant showed mild related adverse effects, including altered taste, dry eyes, eye pain, fatigue, and salivary gland soreness. No blood-related or renal adverse effects were o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XME":"金属与采矿指数ETF-SPDR","CPER":"美国铜指数基金","COPJ":"SPROTT JUNIOR COPPER MINERS ETF","CPXR":"USCF DAILY TARGET 2X COPPER INDEX ETF","CU6.AU":"CLARITY PHARMACEUTICALS LTD","BK7096":"制药","BK4535":"淡马锡持仓"},"translate_title":"Clarity Pharmaceuticals表示，前列腺癌试验参与者通过前列腺特异性抗原实现了检测不到的疾病；股价上涨9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XME":0.79,"CPER":0.79,"COPJ":0.79,"CPXR":0.79,"CU6.AU":1,"MHGmain":0.79,"QCmain":0.79},"content_text":"Clarity Pharmaceuticals (ASX:CU6) said a participant with metastatic castration-resistant prostate cancer in the phase 2 group expansion phase of the SECuRE trial achieved undetectable disease as assessed by prostate-specific antigen and prostate-specific membrane antigen positron emission tomography, according to a Monday Australian bourse filing.The trial is evaluating the safety and efficacy of the company's targeted copper therapy-diagnostic product, copper-67-SAR-bisPSMA, for the potential treatment of prostate cancer.The participant achieved undetectable prostate-specific antigen levels seven weeks after his first cycle of copper-67-SAR-bisPSMA, the filing said. No disease was observed on prostate-specific membrane antigen positron emission tomography after receiving one more cycle of copper-67-SAR-bisPSMA. The participant showed mild related adverse effects, including altered taste, dry eyes, eye pain, fatigue, and salivary gland soreness. No blood-related or renal adverse effects were observed.This is the fifth patient to achieve undetectable disease by radiographic assessment following copper-67-SAR-bisPSMA treatment, per the filing. The company aims to complete participant recruitment for the group expansion phase this year.Clarity Pharmaceuticals' shares rose nearly 9% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613084422","isCrawlerRequest":true}